Compare Riot Platforms Inc (RIOT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Riot Platforms Inc vs Sanofi SA — how do they compare? Riot Platforms Inc trades at $23.28 (market cap $8.12B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 12.9× Riot Platforms Inc's market cap, and Sanofi SA pays a 5.53% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| RIOT | SNY | |
|---|---|---|
Market Cap | $8.12B | $104.85B |
Sector | Technology | Health |
52-Week High | $28.67 | $52.34 |
52-Week Low | $11.03 | $41.33 |
Enterprise Value | $8.79B | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RIOT trades at $19.90, up 8.98% in the past 24 hours, but faces a bearish technical signal despite strong analyst support. The company reported a significant net loss of $663.18 million in 2025 with negative profit margins, though revenue reached $647.44 million. Recent news highlights volatility and strategic partnerships in data center development.
Wall Street remains overwhelmingly bullish with 94% buy ratings and a $28.67 price target, but fundamental weaknesses and cash flow challenges present substantial risks. The stock's outlook depends on improving profitability and successful execution of its business expansion amid competitive pressures.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
